Belharra Therapeutics
@belharratx.com
Belharra Therapeutics, Inc. is a privately held drug discovery company whose novel photoaffinity-based chemoproteomics platform is disrupting the drug discovery paradigm. Guided by a diverse team of biotech trailblazers, Belharra’s proprietary noncovalent drug discovery engine is uniquely capable of identifying novel starting points for transformative medicines to address previously impossible-to-treat diseases and conditions. The company’s next generation chemoproteomics platform enables Belharra scientists to identify small molecule drug candidates for any binding site, on any protein, in any conformational state, in any cell type. Originating with Christopher G. Parker, Ph.D. and John Teijaro, Ph.D. at Scripps Research and pioneers in the field of chemical biology and serial biotech founders Benjamin Cravatt, Ph.D. at Scripps Research and Stuart Schreiber, Ph.D. at the Broad Institute of MIT and Harvard, the four co-founded Belharra Therapeutics in 2021 with a $50M Series A financing from Versant Ventures and incubation at Inception Therapeutics. Belharra is headquartered in the San Francisco Bay Area with its primary lab and offices in San Diego, California.
Belharra Therapeutics's Company Logos
Belharra Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#417BAD
Steel Blue
65, 123, 173
208, 45, 47
62, 29, 0, 32
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#113B4E
Elephant
17, 59, 78
199, 64, 19
78, 24, 0, 69
About Belharra Therapeutics
Belharra Therapeutics is an innovative brand in the field of drug discovery, redefining the traditional approach to target and ligand identification. With a focus on unexplored potential, they offer a new perspective on druggable proteins, challenging the notion that some proteins are untreatable. Traditional drug discovery methods typically target only a small fraction of the proteome, leaving a vast catalog of potential targets unexplored.
Belharra Therapeutics aims to change this by leveraging their proprietary library of non-covalent, small molecules to probe protein targets in their native environment within the cell. This allows them to identify new binding sites that would be difficult to predict using traditional methods. Their platform expands what is possible in drug discovery by exploring the native environment of the cell without being limited by predefined bioassays.
Belharra Therapeutics envisions a world where the entire proteome is druggable, ultimately revolutionizing the treatment of diseases. If you are a fearless innovator with a passion for pushing the boundaries of scientific discovery, join Belharra's mission to redefine the possibilities for patients
Company type
Privately Held
Year founded
2021
Company size
51-200 employees
